Bedel Financial Consulting, Inc. Vaxart, Inc. Transaction History
Bedel Financial Consulting, Inc.
- $645 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding VXRT
# of Institutions
106Shares Held
24.9MCall Options Held
77KPut Options Held
45.8K-
Vanguard Group Inc Valley Forge, PA8.45MShares$5.83 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.19MShares$1.51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.89MShares$1.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.22 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.5MShares$1.03 Million0.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $87.3M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...